Clinical Trial

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT07125872
Lead Sponsor ImmunityBio, Inc.
Conditions Relapsed B-Cell Non Hodgkin Lymphoma
Enrollment 20 participants
Start Date 2025-11-11
Primary Completion 2027-05-25 (estimated)
Study Completion 2028-05-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-04